TY - JOUR
T1 - Primary brain calcification
T2 - an international study reporting novel variants and associated phenotypes
AU - The French PFBC study group
AU - Ramos, Eliana Marisa
AU - Carecchio, Miryam
AU - Lemos, Roberta
AU - Ferreira, Joana
AU - Legati, Andrea
AU - Sears, Renee Louise
AU - Hsu, Sandy Chan
AU - Panteghini, Celeste
AU - Magistrelli, Luca
AU - Salsano, Ettore
AU - Esposito, Silvia
AU - Taroni, Franco
AU - Richard, Anne Claire
AU - Tranchant, Christine
AU - Anheim, Mathieu
AU - Ayrignac, Xavier
AU - Goizet, Cyril
AU - Vidailhet, Marie
AU - Maltete, David
AU - Wallon, David
AU - Frebourg, Thierry
AU - Pimentel, Lylyan
AU - Geschwind, Daniel H.
AU - Vanakker, Olivier
AU - Galasko, Douglas
AU - Fogel, Brent L.
AU - Innes, A. Micheil
AU - Ross, Alison
AU - Dobyns, William B.
AU - Alcantara, Diana
AU - O’Driscoll, Mark
AU - Hannequin, Didier
AU - Campion, Dominique
AU - Oliveira, João R.
AU - Garavaglia, Barbara
AU - Coppola, Giovanni
AU - Nicolas, Gaël
N1 - Funding Information:
Funding This study was cosupported by CNR-MAJ, Inserm, European Union and Région Normandie. Europe gets involved in Normandie with European Regional Development Fund (ERDF) (French group). This study received support from FACEPE, CAPES, and CNPq (310150/2016-7,480255/2013-0, 440770/2016-5; IBPG-0627-2.02/11; IBPG-0162-2.02/14; BFP-0123-2.02/12; BR group). We acknowledge the support of the NINDS Informatics Center for Neurogenetics and Neurogenomics (P30 NS062691), NIH grants R01 NS40752 to DHG, R01NS082094 to BLF, and R01 HL130996 to WBD, the Bev Carrick Memorial Fund to GC (US group), and Cancer Research UK Programme Award C24110/A15394 to MOD. Funding sources had no specific roles.
Publisher Copyright:
© 2018, European Society of Human Genetics.
PY - 2018/10/1
Y1 - 2018/10/1
N2 - Primary familial brain calcification (PFBC) is a rare cerebral microvascular calcifying disorder with a wide spectrum of motor, cognitive, and neuropsychiatric symptoms. It is typically inherited as an autosomal-dominant trait with four causative genes identified so far: SLC20A2, PDGFRB, PDGFB, and XPR1. Our study aimed at screening the coding regions of these genes in a series of 177 unrelated probands that fulfilled the diagnostic criteria for primary brain calcification regardless of their family history. Sequence variants were classified as pathogenic, likely pathogenic, or of uncertain significance (VUS), based on the ACMG-AMP recommendations. We identified 45 probands (25.4%) carrying either pathogenic or likely pathogenic variants (n = 34, 19.2%) or VUS (n = 11, 6.2%). SLC20A2 provided the highest contribution (16.9%), followed by XPR1 and PDGFB (3.4% each), and PDGFRB (1.7%). A total of 81.5% of carriers were symptomatic and the most recurrent symptoms were parkinsonism, cognitive impairment, and psychiatric disturbances (52.3%, 40.9%, and 38.6% of symptomatic individuals, respectively), with a wide range of age at onset (from childhood to 81 years). While the pathogenic and likely pathogenic variants identified in this study can be used for genetic counseling, the VUS will require additional evidence, such as recurrence in unrelated patients, in order to be classified as pathogenic.
AB - Primary familial brain calcification (PFBC) is a rare cerebral microvascular calcifying disorder with a wide spectrum of motor, cognitive, and neuropsychiatric symptoms. It is typically inherited as an autosomal-dominant trait with four causative genes identified so far: SLC20A2, PDGFRB, PDGFB, and XPR1. Our study aimed at screening the coding regions of these genes in a series of 177 unrelated probands that fulfilled the diagnostic criteria for primary brain calcification regardless of their family history. Sequence variants were classified as pathogenic, likely pathogenic, or of uncertain significance (VUS), based on the ACMG-AMP recommendations. We identified 45 probands (25.4%) carrying either pathogenic or likely pathogenic variants (n = 34, 19.2%) or VUS (n = 11, 6.2%). SLC20A2 provided the highest contribution (16.9%), followed by XPR1 and PDGFB (3.4% each), and PDGFRB (1.7%). A total of 81.5% of carriers were symptomatic and the most recurrent symptoms were parkinsonism, cognitive impairment, and psychiatric disturbances (52.3%, 40.9%, and 38.6% of symptomatic individuals, respectively), with a wide range of age at onset (from childhood to 81 years). While the pathogenic and likely pathogenic variants identified in this study can be used for genetic counseling, the VUS will require additional evidence, such as recurrence in unrelated patients, in order to be classified as pathogenic.
UR - http://www.scopus.com/inward/record.url?scp=85049149760&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049149760&partnerID=8YFLogxK
U2 - 10.1038/s41431-018-0185-4
DO - 10.1038/s41431-018-0185-4
M3 - Article
C2 - 29955172
AN - SCOPUS:85049149760
SN - 1018-4813
VL - 26
SP - 1462
EP - 1477
JO - European Journal of Human Genetics
JF - European Journal of Human Genetics
IS - 10
ER -